8-K: Veru Inc. Announces Positive Clinical Trial Progress and Financial Update

Veru Inc. reports FDA clearance for enobosarm obesity study, plans Phase 2b trial, and provides financial highlights for the first fiscal quarter of 2024.

Summary

• Veru Inc. has received FDA clearance for its Investigational New Drug (IND) application for enobosarm, a drug aimed at preserving muscle while augmenting fat loss in patients using GLP-1 weight loss medications.
• The company plans to initiate a Phase 2b clinical study for enobosarm in April 2024, with top-line data expected by the end of the calendar year.
• Veru completed a public offering, raising net proceeds of $35.2 million, bringing their total cash to $40.6 million as of December 31, 2023.
• The company's metabolic disease program focuses on enobosarm, which has shown in previous studies to increase muscle mass and reduce fat mass.
• The Phase 2b trial will evaluate enobosarm in 90 sarcopenic obese or overweight elderly patients receiving a GLP-1 RA, with primary and secondary endpoints focused on lean body mass and total body fat mass at 16 weeks.
• Following the Phase 2b trial, an open-label extension study is planned to assess enobosarm's ability to reverse muscle loss and prevent fat rebound, with results expected in Q2 2025.
• Veru's oncology pipeline includes enobosarm for metastatic breast cancer, but further development is contingent on funding.
• The company's infectious disease pipeline includes sabizabulin for viral-induced ARDS, but further development is also contingent on external funding.
• Veru's FC2 female condom business continues to generate revenue, with over $213 million in net revenue since 2017.
• Net revenues for the first fiscal quarter of 2024 decreased to $2.1 million from $2.5 million in the same period last year, while gross profit increased to $1.2 million from $0.7 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in clinical trials and a recent capital raise. However, there are some concerns about revenue decline and the need for external funding for other programs.

Positives

• The FDA clearance of the IND application for enobosarm is a significant milestone for Veru.
• The company has secured sufficient funding to complete and report top-line results for the Phase 2b enobosarm study.
• Enobosarm has a large safety database, with 27 clinical trials involving 1581 men and women, and was generally well tolerated.
• The company is actively growing its direct-to-patient telehealth portal for FC2, expanding its reach and control over distribution.
• Veru is supplying a large multi-year South African tender for female condoms, which is expected to continue until 2025.

Negatives

• Net revenues decreased to $2.1 million from $2.5 million in the first fiscal quarter of 2024 compared to the same period last year.
• The continued clinical development of enobosarm for metastatic breast cancer is subject to the availability of sufficient funding.
• The company does not plan to advance the Phase 3 development of sabizabulin for viral-induced ARDS without external funding.

Risks

• The success of the Phase 2b enobosarm trial is not guaranteed, and the results may not meet the desired endpoints.
• The company's ability to secure external funding for its oncology and infectious disease pipelines is uncertain.
• The company's financial performance is subject to market conditions and the success of its commercial products.
• There are risks associated with the development of new drugs, including regulatory hurdles and clinical trial failures.

Future Outlook

Veru plans to focus on the clinical development of enobosarm for obesity and oncology, while also seeking external funding for its infectious disease pipeline. The company expects to complete the Phase 2b enobosarm trial and report top-line results by the end of 2024, and the open-label extension study results in Q2 2025. The company also plans to continue to grow its FC2 business.

Management Comments

• Mitchell Steiner, M.D., Chairman, President, and CEO of Veru Inc., stated that the FDA clearance of the IND application for enobosarm is a significant milestone.
• Dr. Steiner believes that enobosarm could effectively meet the critical unmet medical need for higher quality weight loss by preserving muscle and augmenting fat loss.
• Management believes that current funds are sufficient to complete and report topline results for the Phase 2b enobosarm study.

Industry Context

The announcement is relevant to the growing market for obesity treatments, particularly those that address muscle loss associated with GLP-1 drugs. The focus on sarcopenic obesity and the potential for enobosarm to preserve muscle mass while augmenting fat loss positions Veru in a competitive space with other companies developing weight loss therapies.

Comparison to Industry Standards

• The focus on preserving muscle mass during weight loss is a key differentiator for Veru, as many current GLP-1 therapies can lead to muscle loss, which is a concern, especially for older adults.
• Companies like Novo Nordisk and Eli Lilly are leading the GLP-1 market with drugs like Ozempic and Mounjaro, but they do not specifically address muscle loss, which is a potential advantage for Veru's enobosarm.
• The Phase 2b trial design, focusing on sarcopenic obese patients, is aligned with the growing recognition of the need for targeted therapies for this specific population.
• The large safety database for enobosarm, with 27 clinical trials and 1581 patients, is a positive sign compared to some newer drugs with less extensive safety data.

Stakeholder Impact

• Shareholders will be impacted by the clinical trial progress and the company's financial performance.
• Employees will be impacted by the company's strategic focus and the potential for growth.
• Patients may benefit from the development of new treatments for obesity and other diseases.
• Customers of FC2 will be impacted by the company's efforts to expand its reach and distribution.

Next Steps

• Initiate the Phase 2b clinical study for enobosarm in April 2024.
• Complete the Phase 2b enobosarm trial and report top-line results by the end of 2024.
• Continue into an open-label extension study after the Phase 2b trial.
• Seek external funding for the oncology and infectious disease pipelines.
• Continue to grow the FC2 business and expand its telehealth reach.

Key Dates

Keywords

enobosarm, obesity, GLP-1, muscle loss, weight loss, sarcopenic obesity, clinical trial, FDA, FC2, female condom, metabolic disease, oncology, ARDS, sabizabulin